A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma
Complete title: A phase 1, open-label, dose-esclation study of SGN-CD19B in patients with relapsed or refractory aggressive B-Cell non-Hodgkin lymphoma
The study will examine the safety profile of SGN-CD19B administered as a single agent. The main purpose of the study is to estimate the highest dose that does not cause unacceptable side effects of SGN-CD19B in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) subtypes of diffuse large B-cell lymphoma (DLBCL) and Grade 3 follicular lymphoma (FL3). Additionally, the pharmacokinetic profile and antitumor activity of SGN-CD19B will be assessed.
** For Eligibility information, please click on the "Look up trial at NIH" link above. **
Other eligibility criteria may apply.
|Seattle Cancer Care Alliance Intake Office
|800-804-8824 / 206-606-1024
Hematologic Malignancies; Lymphoma; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin (NHL); Immunoproliferative Disorders; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Immune System Diseases
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.